In summary, by analyzing the clinical features, gene mutation information, and factors affecting the prognosis of 105 SMARCA4‐dNSCLC patients, we demonstrated that SMARCA4‐dNSCLC is a type of tumor distinct from SMARCA4‐iNSCLC, with poor prognosis and high invasiveness. This evidence concerns the gene SMARCA4 and neoplasm.